I agree that this site is using cookies. You can find further informations here.
X
Ruiz-Borrego, Manuel
643  results:
Search for persons X
?
1

3-year invasive disease-free survival with chemotherapy de-..:

Pérez-García, José Manuel ; Cortés, Javier ; Ruiz-Borrego, Manuel...
The Lancet.  403 (2024)  10437 - p. 1649-1659 , 2024
Link: https://doi.org/10.1016/..
 
?
2

Correlation between trophoblast cell-surface antigen-2 (Tro..:

Gion, María ; García-Mosquera, Juan José ; Pérez-García, José Manuel...
Breast Cancer Research and Treatment.  205 (2024)  3 - p. 589-598 , 2024
Link: https://doi.org/10.1007/..
 
?
3

Clinicopathological and molecular predictors of [18F]FDG-PE..:

Llombart-Cussac, Antonio ; Prat, Aleix ; Pérez-García, José Manuel...
European Journal of Nuclear Medicine and Molecular Imaging.  51 (2024)  9 - p. 2733-2743 , 2024
Link: https://doi.org/10.1007/..
 
?
4

Impact of coadministration of proton-pump inhibitors and pa..:

Di Cosimo, Serena ; Pérez-García, José Manuel ; Bellet, Meritxell...
The Breast.  76 (2024)  - p. 103761 , 2024
Link: https://doi.org/10.1016/..
 
?
5

Real-world experience with pertuzumab and trastuzumab combi..:

Falcón González, Alejandro ; Cruz Jurado, Josefina ; Llabrés Valenti, Elisenda...
Clinical and Translational Oncology.  , 2024
Link: https://doi.org/10.1007/..
 
?
6

Long-term outcomes of high-risk HR-positive and HER2-negati..:

Martín, Miguel ; Carrasco, Eva ; Rodríguez-Lescure, Álvaro...
Breast Cancer Research and Treatment.  201 (2023)  2 - p. 151-159 , 2023
Link: https://doi.org/10.1007/..
 
?
7

Impact of the 21-Gene Assay in Patients with High-Clinical ..:

Llombart-Cussac, Antonio ; Anton-Torres, Antonio ; Rojas, Beatriz...
Cancers.  15 (2023)  5 - p. 1529 , 2023
Link: https://doi.org/10.3390/..
 
?
8

CCNE1andPLK1Mediate Resistance to Palbociclib in HR+/HER2− ..:

Guerrero-Zotano, Ángel ; Belli, Stefania ; Zielinski, Christoph...
Clinical Cancer Research.  29 (2023)  8 - p. 1557-1568 , 2023
Link: https://doi.org/10.1158/..
 
?
9

Baseline Mutations and ctDNA Dynamics as Prognostic and Pre..:

Pascual, Javier ; Gil-Gil, Miguel ; Proszek, Paula...
Clinical Cancer Research.  29 (2023)  20 - p. 4166-4177 , 2023
Link: https://doi.org/10.1158/..
 
?
10

Final findings from the CONTROL trial: Strategies to reduce..:

Chan, Arlene ; Ruiz-Borrego, Manuel ; Marx, Gavin...
The Breast.  67 (2023)  - p. 94-101 , 2023
Link: https://doi.org/10.1016/..
 
?
11

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data..:

Cejuela, Mónica ; Gil-Torralvo, Ana ; Castilla, M. Ángeles...
International Journal of Molecular Sciences.  24 (2023)  10 - p. 8488 , 2023
Link: https://doi.org/10.3390/..
 
?
12

Neoadjuvant nivolumab + palbociclib + anastrozole for oestr..:

Jerusalem, Guy ; Prat, Aleix ; Salgado, Roberto...
The Breast.  72 (2023)  - p. 103580 , 2023
Link: https://doi.org/10.1016/..
 
?
13

Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predi..:

Asleh, Karama ; Lluch, Ana ; Goytain, Angela...
Clinical Cancer Research.  29 (2022)  2 - p. 389-400 , 2022
Link: https://doi.org/10.1158/..
 
?
14

Dual neoadjuvant blockade plus chemotherapy versus monother..:

Vazquez, Juan Carlos ; Antolin, Silvia ; Ruiz-Borrego, Manuel...
Clinical and Translational Oncology.  25 (2022)  4 - p. 941-958 , 2022
Link: https://doi.org/10.1007/..
 
?
15

Palbociclib Rechallenge for Hormone Receptor–Positive/HER-N..:

Albanell, Joan ; Pérez-García, José Manuel ; Gil-Gil, Miguel...
Clinical Cancer Research.  29 (2022)  1 - p. 67-80 , 2022
Link: https://doi.org/10.1158/..
 
1-15